FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2596275698> ?p ?o ?g. }

• W2596275698 endingPage "S96" @default.
• W2596275698 startingPage "S96" @default.
• W2596275698 abstract "Purpose/Objective(s)CD11a is a cellular adhesion molecule, and its expression is required for the rejection of tumors. We previously reported that PD-1 blockade enhanced the RT-induced abscopal effect in melanoma and renal cell carcinoma preclinical models; therefore, we characterized CD11ahighCD8+ T cells from the tumor infiltrating lymphocytes (TILs) of our wild type (WT) and PD-1 knockout (KO) melanoma models (positive for PD-L1).Materials/MethodsC57BL/6 WT or PD-1 KO mice were injected subcutaneously with 1×105 B16-OVA cells in the right hind limb (irradiated) on day 0 and in the left flank (non-irradiated) on days 3–4. On day 8, 15 Gy x 1 was administered to the right hind limb tumors. For the in vitro challenge, 5–10×105 TILs were cultured with OVA peptide (1 μl/mL) for 4–5 hours in the presence of 1 μl/mL of Brefadin A, washed and incubated with rat antimouse CD16/CD32 mAb (2.4G2) to block nonspecific binding, and then stained with CD8-PE-Cy5 and IFN-γ-FITC or control antibodies according to the manufacturer’s instructions. Tumor antigen specific CD8 T cells were identified by OVA-tetramer staining. Cells were analyzed using single laser, analytical flow cytometer and cytometry data analysis software. Statistical analyses were performed using commercial scientific 2D graphing and statistics software. A two-sided, unpaired, or paired Student t-test was used to assess statistical differences in experimental groups. A P-value of < .05 was considered statistically significant.ResultsPD-1 expressed by CD11ahighCD8+ T cells was higher in the irradiated tumors as compared with those of the non-irradiated tumors (P < .05 on day 15). In contrast, CD11ahighCD8+ T cells in the TILs of non-irradiated mice expressed only modest levels of PD-1. After in vitro OVA stimulation, 33–61% of PD-1+ CD11ahighCD8 T cells from the irradiated and non-irradiated tumors produced IFN-g, thereby suggesting that this population is that of the tumor antigen-reactive effector T cells. A higher percentage of CD11ahighCD8+ T cells were noted in the irradiated and non-irradiated tumors of PD-1 KO mice when compared with WT following RT, which correlated with the extent of tumor growth delay in PD-1 KOs. CD11ahigh but not CD11alowCD8+ T cells from both WT and PD-1 KO mice demonstrated tumor antigen specificity by binding to OVA tetramer. CD11ahighCD8+ T cells from the TILs of irradiated PD-1 KO mice produced IFN-g upon OVA peptide stimulation, in contrast to those from the TILs of non-irradiated mice.ConclusionThe CD11ahighCD8 T cell phenotype within TILs identifies tumor-specific effector cells whose frequency and function are enhanced by RT and PD-1 blockade, which in turn correlates with tumor growth delay and the abscopal effect. The combination of RT and PD-1 blockade may be a promising therapeutic approach for managing metastatic cancer patients, and CD11ahighCD8 T cells in the TILs may predict favorable responders to combined RT and anti-PD-1 therapy. Purpose/Objective(s)CD11a is a cellular adhesion molecule, and its expression is required for the rejection of tumors. We previously reported that PD-1 blockade enhanced the RT-induced abscopal effect in melanoma and renal cell carcinoma preclinical models; therefore, we characterized CD11ahighCD8+ T cells from the tumor infiltrating lymphocytes (TILs) of our wild type (WT) and PD-1 knockout (KO) melanoma models (positive for PD-L1). CD11a is a cellular adhesion molecule, and its expression is required for the rejection of tumors. We previously reported that PD-1 blockade enhanced the RT-induced abscopal effect in melanoma and renal cell carcinoma preclinical models; therefore, we characterized CD11ahighCD8+ T cells from the tumor infiltrating lymphocytes (TILs) of our wild type (WT) and PD-1 knockout (KO) melanoma models (positive for PD-L1). Materials/MethodsC57BL/6 WT or PD-1 KO mice were injected subcutaneously with 1×105 B16-OVA cells in the right hind limb (irradiated) on day 0 and in the left flank (non-irradiated) on days 3–4. On day 8, 15 Gy x 1 was administered to the right hind limb tumors. For the in vitro challenge, 5–10×105 TILs were cultured with OVA peptide (1 μl/mL) for 4–5 hours in the presence of 1 μl/mL of Brefadin A, washed and incubated with rat antimouse CD16/CD32 mAb (2.4G2) to block nonspecific binding, and then stained with CD8-PE-Cy5 and IFN-γ-FITC or control antibodies according to the manufacturer’s instructions. Tumor antigen specific CD8 T cells were identified by OVA-tetramer staining. Cells were analyzed using single laser, analytical flow cytometer and cytometry data analysis software. Statistical analyses were performed using commercial scientific 2D graphing and statistics software. A two-sided, unpaired, or paired Student t-test was used to assess statistical differences in experimental groups. A P-value of < .05 was considered statistically significant. C57BL/6 WT or PD-1 KO mice were injected subcutaneously with 1×105 B16-OVA cells in the right hind limb (irradiated) on day 0 and in the left flank (non-irradiated) on days 3–4. On day 8, 15 Gy x 1 was administered to the right hind limb tumors. For the in vitro challenge, 5–10×105 TILs were cultured with OVA peptide (1 μl/mL) for 4–5 hours in the presence of 1 μl/mL of Brefadin A, washed and incubated with rat antimouse CD16/CD32 mAb (2.4G2) to block nonspecific binding, and then stained with CD8-PE-Cy5 and IFN-γ-FITC or control antibodies according to the manufacturer’s instructions. Tumor antigen specific CD8 T cells were identified by OVA-tetramer staining. Cells were analyzed using single laser, analytical flow cytometer and cytometry data analysis software. Statistical analyses were performed using commercial scientific 2D graphing and statistics software. A two-sided, unpaired, or paired Student t-test was used to assess statistical differences in experimental groups. A P-value of < .05 was considered statistically significant. ResultsPD-1 expressed by CD11ahighCD8+ T cells was higher in the irradiated tumors as compared with those of the non-irradiated tumors (P < .05 on day 15). In contrast, CD11ahighCD8+ T cells in the TILs of non-irradiated mice expressed only modest levels of PD-1. After in vitro OVA stimulation, 33–61% of PD-1+ CD11ahighCD8 T cells from the irradiated and non-irradiated tumors produced IFN-g, thereby suggesting that this population is that of the tumor antigen-reactive effector T cells. A higher percentage of CD11ahighCD8+ T cells were noted in the irradiated and non-irradiated tumors of PD-1 KO mice when compared with WT following RT, which correlated with the extent of tumor growth delay in PD-1 KOs. CD11ahigh but not CD11alowCD8+ T cells from both WT and PD-1 KO mice demonstrated tumor antigen specificity by binding to OVA tetramer. CD11ahighCD8+ T cells from the TILs of irradiated PD-1 KO mice produced IFN-g upon OVA peptide stimulation, in contrast to those from the TILs of non-irradiated mice. PD-1 expressed by CD11ahighCD8+ T cells was higher in the irradiated tumors as compared with those of the non-irradiated tumors (P < .05 on day 15). In contrast, CD11ahighCD8+ T cells in the TILs of non-irradiated mice expressed only modest levels of PD-1. After in vitro OVA stimulation, 33–61% of PD-1+ CD11ahighCD8 T cells from the irradiated and non-irradiated tumors produced IFN-g, thereby suggesting that this population is that of the tumor antigen-reactive effector T cells. A higher percentage of CD11ahighCD8+ T cells were noted in the irradiated and non-irradiated tumors of PD-1 KO mice when compared with WT following RT, which correlated with the extent of tumor growth delay in PD-1 KOs. CD11ahigh but not CD11alowCD8+ T cells from both WT and PD-1 KO mice demonstrated tumor antigen specificity by binding to OVA tetramer. CD11ahighCD8+ T cells from the TILs of irradiated PD-1 KO mice produced IFN-g upon OVA peptide stimulation, in contrast to those from the TILs of non-irradiated mice. ConclusionThe CD11ahighCD8 T cell phenotype within TILs identifies tumor-specific effector cells whose frequency and function are enhanced by RT and PD-1 blockade, which in turn correlates with tumor growth delay and the abscopal effect. The combination of RT and PD-1 blockade may be a promising therapeutic approach for managing metastatic cancer patients, and CD11ahighCD8 T cells in the TILs may predict favorable responders to combined RT and anti-PD-1 therapy. The CD11ahighCD8 T cell phenotype within TILs identifies tumor-specific effector cells whose frequency and function are enhanced by RT and PD-1 blockade, which in turn correlates with tumor growth delay and the abscopal effect. The combination of RT and PD-1 blockade may be a promising therapeutic approach for managing metastatic cancer patients, and CD11ahighCD8 T cells in the TILs may predict favorable responders to combined RT and anti-PD-1 therapy." @default.
• W2596275698 created "2017-03-23" @default.
• W2596275698 creator A5001422801 @default.
• W2596275698 creator A5020227451 @default.
• W2596275698 creator A5021301950 @default.
• W2596275698 creator A5040197178 @default.
• W2596275698 creator A5048628138 @default.
• W2596275698 creator A5068287021 @default.
• W2596275698 creator A5078857463 @default.
• W2596275698 creator A5079400879 @default.
• W2596275698 date "2015-11-01" @default.
• W2596275698 modified "2023-10-18" @default.
• W2596275698 title "CD11ahighCD8+ T Cell Phenotype Identifies Tumor Specific Effector Cells Whose Frequency and Function Are Enhanced by RT" @default.
• W2596275698 doi "https://doi.org/10.1016/j.ijrobp.2015.07.230" @default.
• W2596275698 hasPublicationYear "2015" @default.
• W2596275698 type Work @default.
• W2596275698 sameAs 2596275698 @default.
• W2596275698 citedByCount "0" @default.
• W2596275698 crossrefType "journal-article" @default.
• W2596275698 hasAuthorship W2596275698A5001422801 @default.
• W2596275698 hasAuthorship W2596275698A5020227451 @default.
• W2596275698 hasAuthorship W2596275698A5021301950 @default.
• W2596275698 hasAuthorship W2596275698A5040197178 @default.
• W2596275698 hasAuthorship W2596275698A5048628138 @default.
• W2596275698 hasAuthorship W2596275698A5068287021 @default.
• W2596275698 hasAuthorship W2596275698A5078857463 @default.
• W2596275698 hasAuthorship W2596275698A5079400879 @default.
• W2596275698 hasConcept C104317684 @default.
• W2596275698 hasConcept C127716648 @default.
• W2596275698 hasConcept C14036430 @default.
• W2596275698 hasConcept C1491633281 @default.
• W2596275698 hasConcept C203014093 @default.
• W2596275698 hasConcept C502942594 @default.
• W2596275698 hasConcept C51785407 @default.
• W2596275698 hasConcept C54355233 @default.
• W2596275698 hasConcept C71924100 @default.
• W2596275698 hasConcept C86803240 @default.
• W2596275698 hasConcept C95444343 @default.
• W2596275698 hasConceptScore W2596275698C104317684 @default.
• W2596275698 hasConceptScore W2596275698C127716648 @default.
• W2596275698 hasConceptScore W2596275698C14036430 @default.
• W2596275698 hasConceptScore W2596275698C1491633281 @default.
• W2596275698 hasConceptScore W2596275698C203014093 @default.
• W2596275698 hasConceptScore W2596275698C502942594 @default.
• W2596275698 hasConceptScore W2596275698C51785407 @default.
• W2596275698 hasConceptScore W2596275698C54355233 @default.
• W2596275698 hasConceptScore W2596275698C71924100 @default.
• W2596275698 hasConceptScore W2596275698C86803240 @default.
• W2596275698 hasConceptScore W2596275698C95444343 @default.
• W2596275698 hasIssue "3" @default.
• W2596275698 hasLocation W25962756981 @default.
• W2596275698 hasOpenAccess W2596275698 @default.
• W2596275698 hasPrimaryLocation W25962756981 @default.
• W2596275698 hasRelatedWork W1490200385 @default.
• W2596275698 hasRelatedWork W1640078589 @default.
• W2596275698 hasRelatedWork W1750541350 @default.
• W2596275698 hasRelatedWork W2125393542 @default.
• W2596275698 hasRelatedWork W2794362477 @default.
• W2596275698 hasRelatedWork W3177318975 @default.
• W2596275698 hasRelatedWork W4200343853 @default.
• W2596275698 hasRelatedWork W4256076210 @default.
• W2596275698 hasRelatedWork W4283456975 @default.
• W2596275698 hasRelatedWork W2991947828 @default.
• W2596275698 hasVolume "93" @default.
• W2596275698 isParatext "false" @default.
• W2596275698 isRetracted "false" @default.
• W2596275698 magId "2596275698" @default.
• W2596275698 workType "article" @default.